Find a trial missing? Please e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.

 

ID Phase Actuator Vector Target Cells Sponsor Condition Results
NCT03326336 (PIONEER) I/IIa ChrimsonR AAV 2.7m8 RGC GenSight Biologic RP Case report: Object localization in near spase, EEG ( Sahel et al., 2021)
NCT04945772 (RESTORE), NCT06162585 I/II + Und Follow-Up Studie MCO-010 AAV2 BC Nanoscope Therapeutics RP Press release: Significant improvement in VA ( FirstWord, 2025; Nanoscope Therapeutics, 2024 )
NCT04919473, NCT05921162 I/II + Und Follow-Up Studie MCO-1 / vMCO-010 AAV2 BC Nanoscope Therapeutics RP, ABCA4-associated Case Series: Improvement in VA, visual field and Quality of Life, no controls included (Mohanty et al., 2025 )
NCT05417126 (STARLIGHT), NCT06048185 II + Und Follow-Up Studie vMCO-010 AAV2 BC Nanoscope Therapeutics M. Stargardt Case Series: Improvement in VA, visual field and Quality of Life, no controls included (Lam et al., 2025)
NCT02556736 I/IIa ChR2 AAV2.7m8 RGC AbbVie/RetroSense RP Conference report (Bunnell, Yuan, Lopez, 2025)
NCT04278131 I/II ChronosFP AAV2 RGC Bionic Sight RP Press release: Increase in light sensitivity and VA ( Bionic Sight, 2025 )
NCT06460844 (ENVISION) I ChRown ARMMs RGC Ray Therapeutics RP, Choroideremia Sponsor's webpage ( Ray Therapeutics, 2025)
NCT06292650 I PsCatCh2.0 AAV? RGC Zhongmou Therapeutics RP Conference report: VA improvement (Zhou et al., 2025)
ChiCTR2200062174 ? ? AAV? ? Ugenex Therapeutics PR Conference report: VA improvement (Luo et al., 2025)